
What is claimed is:

1. A compound having the Formula **I-2**:




I


or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates thereof, wherein:

X is O, S, NH or N-CN;

Ring A is formula A-1 or A-2



A-1



A-2

Y is H, halogen, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkyl [optionally substituted with 1-5 fluoros], cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-6C)alkoxy [optionally substituted with 1-5 fluoros], CN, aminocarbonyl or (1-4C alkoxy)carbonyl;

R^a, R^b and R^c are independently selected from H, halogen, (1-3C)alkyl, (1-3C)alkoxy and CN;

B is NR^1, O, a bond, CR^dR^e, S or SO_2;

D is NR^1, O, a bond, CR^fR^g, S or SO_2;

E is NR^1, O, a bond, or CR^hR^i, S or SO_2;

F is CR^jR^k;

provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms and zero or one of B, D or E is NR^1 or O;

G is CR^mR^n;

K is NR^1;

R^1 is (1-6C)alkyl [optionally substituted with one to five fluoros], (1-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], (1-6C)alkylC(=O)- or (1-6C alkoxy)C=O-;

R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently H, OH, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], (2-6C)cyanoalkyl, (1-6C)alkoxy [optionally substituted with one to five fluoros], or (1-3C alkoxy)(2-6C)alkoxy [optionally substituted with one to five fluoros],

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k, together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring,

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group,

and wherein only one of R^d and R^e can be OH and neither is OH if B is connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom;


R^m is H, (1-3C)alkyl [optionally substituted with 1-5 fluoros], cyclopropyl or cyclobutyl, and

R^n is H or (1-3C)alkyl [optionally substituted with 1-5 fluoros], or


R^m and R^n together form an oxo group;

R^p is H, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], or (2-6C)cyanoalkyl;

Ring C is formula **C-1** or **C-2**



C-1



C-2 ;

R^3 is (1-6C)alkyl, hydroxy(1-6C)alkyl, Ar^2, $hetCyc^1$, (3-7C)cycloalkyl, or $hetAr^2$;

Ar^2 is phenyl optionally substituted with one or more groups independently selected from halogen and (1-6C)alkyl;

$hetCyc^1$ is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

$hetAr^2$ is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen;

R^4 is OH, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, amino(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-3C)alkylsulfonamido(1-6C)alkyl, sulfamido(1-6C)alkyl, hydroxycarbonyl(1-6C)alkyl, $hetAr^3$(1-6C)alkyl, Ar^3(1-6C)alkyl, (1-6C)alkoxy, monofluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, hydroxyl-carbonyl(1-6C)alkoxy, $hetCyc^2$(1-6C)alkoxy, $hetAr^3$(1-6C)alkoxy, Ar^3(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (1-3C alkylsulfonyl)(1-6C)alkoxy, (3-6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(1-6C)alkyl], $hetAr^4$, $hetAr^4$-O-, Ar^4, $hetCyc^2(O)CH_2$-, (1-4C alkoxycarbonyl)(1-6C)alkoxy, hydroxycarbonyl(1-6C)alkoxy, aminocarbonyl(1-6C)alkoxy, $hetCyc^2C(=O)$(1-6C)alkoxy, hydroxy(1-3C alkoxy)(1-6C)alkoxy, hydroxytrifluoro(1-6C)alkoxy, (1-3C)alkylsulfonamido(1-6C)alkoxy, (1-3C)alkylamido(1-6C)alkoxy, di(1-3C alkyl)amino-carboxy, $hetCyc^2C(=O)O$-, hydroxydifluoro(1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, (1-6C)alkoxycarbonyl, hydroxylcarbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, $hetCyc^3$, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)oxadiazolonyl, $hetAr^5$ or $hetCyc^4$-O-;

$hetCyc^2$ is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, and (1-6C)acyl;

$hetCyc^3$ is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, (1-6C)alkyl, trifluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, (1-6C)acyl-, (1-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl;


$hetAr^3$ is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (1-6C)alkyl;

Ar^3 is phenyl optionally substituted with (1-4C)alkoxy;

$hetAr^4$ is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with one or more substituents independently

selected from (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl, trifluoro(1-6C)alkyl, difluoro(1-6C)alkyl, fluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH_2- (3-6C cycloalkyl)C(=O)-, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylsulfonyl, NH_2, (1-6C alkyl)amino, di(1-6C alkyl)amino, (1-3C trifluoroalkoxy), fluoro(1-6C alkyl)amino, difluoro(1-6C alkyl)amino, trifluoro(1-6C alkyl)amino, and (3-4C cycloalkyl)amino;

$hetAr^5$ is a group selected from the structures:



where R^z is (3-4C)cycloalkyl or (1-3C)alkyl (optionally substituted with 1-3 fluoros), wherein each of said $hetAr^5$ groups is optionally further substituted with one or more groups independently selected from F and (1-3C)alkyl optionally substituted with 1-3 fluoros;

$hetCyc^4$ is a 7-8 membered bridged heterocycle having a ring nitrogen atom and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen;

Ar^4 is phenyl optionally substituted with one or more groups independently selected from (1-6C)alkyl, halogen, CN, CF_3, CF_3O-, (1-6C)alkoxy, (1-6Calkyl)OC(=O)-, aminocarbonyl, (1-6C)alkylthio, hydroxy(1-6C)alkyl, (1-6C alkyl)SO_2-, HOC(=O)- and (1-3C alkoxy)(1-3C alkyl)OC(=O)-;

R^5 is (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl, (1-4C alkyl)OC(=O)-, (1-6C)alkylthio, (3-4C)cycloalkyl, amino, aminocarbonyl, trifluoro(1-3C alkyl)amido, or phenyl (optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy); or

R^4 and R^5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, or

R^4 and R^5 together with the atoms to which they are attached form 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or two

substituents independently selected from (1-6C alkyl)C(=O)O-, (1-6C)acyl, (1-6C)alkyl and oxo, and said sulfur ring atom is optionally oxidized to S(=O) or SO_2;

R^{3a} is halogen, (1-6C)alkyl, trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen and (1-6C)alkyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen;

R^{4a} is hydrogen, (1-6C)alkyl, trifluoro(1-6C)alkyl, phenyl [optionally substituted with one or more groups independently selected from (1-6C)alkyl, halogen, CN, CF_3, CF_3O-, (1-6C)alkoxy, (1-6Calkyl)OC(=O)-, aminocarbonyl, (1-6C)alkylthio, hydroxy(1-6C)alkyl, (1-6C alkyl)SO_2-, HOC(=O)- and (1-3C alkoxy)(1-3C alkyl)OC(=O)-] or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (1-6C)alkyl, hydroxy(1-6C)alkyl, trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH_2- (3-6C cycloalkyl)C(=O)-, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylsulfonyl, NH_2, (1-6C alkyl)amino, di(1-6C alkyl)amino and (1-3C trifluoroalkoxy)(1-3C)trifluoroalkyl; and

R^{5a} is halogen, (1-6C)alkyl, trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen and (1-6C)alkyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen.

2. A compound according to claim 1, wherein X is O.

3. A compound according to claim 1, wherein X is S.

4. A compound according to any of claims 1-3, wherein zero to four of R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently H, OH, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], (2-6C)cyanoalkyl, (1-6C)alkoxy [optionally substituted with one to five fluoros], or (1-3C alkoxy)(2-6C)alkoxy [optionally substituted with one to five fluoros],

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k, together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring, or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group, and the remainder are hydrogen, wherein only one of R^d and R^e can be OH and neither is OH if B is

connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom.

5. A compound according to claim 4, wherein zero to two of R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently OH, methyl, methoxy, $CH_3OCH_2CH_2O$-, or cyclopropyl,

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring, or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group, and the remainder are hydrogen, wherein only one of R^d and R^e can be OH and neither is OH if B is connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom.

6. A compound according to any of claims 1-5, wherein Ring A is A-1.

7. A compound according to claim 6, wherein B is a bond or CR^dR^e, D is a bond or CR^fR^g, E is a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms.

8. A compound according to claim 6, wherein B is O, a bond or CR^dR^e, D is O, a bond or CR^fR^g, E is O, a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms and contains one oxygen atom.

9. A compound according to claim 6, wherein B is NR^1, a bond or CR^dR^e, D is NR^1, a bond or CR^fR^g, E is NR^1, a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms and contains one nitrogen atom.

10. A compound according to claim 6, wherein B is a NR^1 or O, D is a bond or CR^fR^g, E is a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms.

11. A compound according to claim 6, wherein B is a bond or CR^dR^e, D is NR^1 or O, E is a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms.

12. A compound according to any of claims 1-5, wherein Ring A is A-2.

13. A compound according to any of claims 1-12, wherein Y is H, halogen or (1-3C alkoxy)(1-6C)alkyl.

14. A compound according to any of claims 1-13, wherein R^a, R^b and R^c are independently selected from halogen, (1-3C)alkyl, (1-3C)alkoxy and CN.

15. A compound according to any of claims 1-14, wherein Ring C is formula C-1.

16. A compound according to claim 15, wherein:

R^4 is OH, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, amino(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-3C)alkylsulfonamido(1-6C)alkyl, sulfamido(1-6C)alkyl, hydroxycarbonyl(1-6C)alkyl, $hetAr^3$(1-6C)alkyl, Ar^3(1-6C)alkyl, (1-6C)alkoxy, monofluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, hydroxylcarbonyl(1-6C)alkoxy, $hetCyc^2$(1-6C)alkoxy, $hetAr^3$(1-6C)alkoxy, Ar^3(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (1-3C alkylsulfonyl)(1-6C)alkoxy, (3-6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(1-6C)alkyl], $hetAr^4$, $hetAr^4$-O-, Ar^4, $hetCyc^2(O)CH_2$-, (1-4C alkoxycarbonyl)(1-6C)alkoxy, hydroxycarbonyl(1-6C)alkoxy, aminocarbonyl(1-6C)alkoxy, $hetCyc^2C(=O)$(1-6C)alkoxy, hydroxy(1-3C alkoxy)(1-6C)alkoxy, hydroxytrifluoro(1-6C)alkoxy, (1-3C)alkylsulfonamido(1-6C)alkoxy, (1-3C)alkylamido(1-6C)alkoxy, di(1-3C alkyl)amino-carboxy, $hetCyc^2C(=O)O$-, hydroxydifluoro(1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, (1-6C)alkoxycarbonyl, hydroxylcarbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, $hetCyc^3$, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)oxadiazolonyl, or $hetAr^5$;

and

R^5 is (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl, (1-4C alkyl)OC(=O)-, (1-6C)alkylthio, (3-4C)cycloalkyl, amino, aminocarbonyl, trifluoro(1-3C alkyl)amido, or phenyl (optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy).

17. A compound according to claim 16, wherein R^4 is selected from (1-6C)alkyl, trifluoro(1-6C)alkyl, cyano(1-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (3-6C)cycloalkyl, $hetAr^4$ and $hetAr^5$.

18. A compound according to claim 16, wherein R^4 is selected from (1-6C)alkoxy, $hetAr^4$ and $hetAr^5$.

19. A compound according to claim 17, wherein R^4 is $hetAr^4$ or $hetAr^5$.

20. A compound according to any of claims 1-19, wherein R^5 is selected from halogen, CN, (1-6C)alkyl, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy.

21. A compound according to claim 20, wherein R^5 is selected from halogen and (1-6C)alkyl.

22. A compound according to claim 21, wherein R^5 is (1-6C)alkyl.

23. A compound according to claim 15, wherein:

R^4 and R^5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, or

R^4 and R^5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=O)O-, or (1-6)acyl, and said sulfur ring atom is optionally oxidized to S(=O) or SO_2.

24. A compound according to any of claims 1-23, wherein R^3 is selected from Ar^2, $hetAr^2$ and (1-6C)alkyl.

25. A compound according to any of claims 1-24, wherein R^3 is selected from Ar^2 and (1-6C)alkyl.

26. A compound according to claim 25, wherein R^3 is Ar^2.

27. A compound according to claim 1, selected from a compound of Examples 1-160 or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

29. A method for treating a disease or disorder selected from pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof.

30. The method of claim 29, wherein the method is a method of treating pain.

31. The method of claim 29, wherein said cancer is a cancer having a dysregulation of TrkA.


32. The method of claim 31, wherein said cancer is selected from non-small cell lung cancer, papillary thyroid carcinoma, glioblastoma multiforme, acute myeloid leukemia, colorectal carcinoma, large cell neuroendocrine carcinoma, prostate cancer, neuroblastoma, pancreatic carcinoma, melanoma, head and neck squamous cell carcinoma and gastric carcinoma.

33. A compound of Formula **I** as defined in any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, for use in the treatment of pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

34. Use of a compound of Formula **I** as defined in any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.


35. A process for the preparation of a compound of claim 1, which comprises:

(a) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **III**



III


in the presence carbonyldiimidazole or triphosgene and a base; or

(b) for a compound of Formula **I** where X is S, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **III**



III


in the presence di(1H-imidazol-2-yl)methanethione and a base; or

(c) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **IV**



IV


where L^1 is a leaving group, in the presence of a base; or

(d) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **V**



V


where L^2 is a leaving group, with a corresponding compound having the formula **III**



III


in the presence of a base; or

(e) for a compound of Formula **I** where X is O, activating a corresponding compound having the formula **VI**



VI


with diphenylphosphoryl azide followed by coupling the activated intermediate with a corresponding compound having the formula **III**



III


in the presence a base; or

(f) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **VII**



VII


in the presence of a base; or

(g) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **VIII**



VIII

with a corresponding compound having the formula **III**




III

in the presence of a base; and

optionally removing protecting groups and optionally preparing a pharmaceutically acceptable salt thereof.

Claims

1. A compound having the Formula **I**:




I


or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates thereof, wherein:

X is O, S, NH or N-CN;

Ring A is formula A-1 or A-2



A-1



A-2

Y is H, halogen, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkyl [optionally substituted with 1-5 fluoros], cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-6C)alkoxy [optionally substituted with 1-5 fluoros], CN, aminocarbonyl or (1-4C alkoxy)carbonyl;

R^a, R^b and R^c are independently selected from H, halogen, (1-3C)alkyl, (1-3C)alkoxy and CN;

B is NR^1, O, a bond, CR^dR^e, S or SO_2;

D is NR^1, O, a bond, CR^fR^g, S or SO_2;

E is NR^1, O, a bond, or CR^hR^i, S or SO_2;

F is CR^jR^k;

provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms and zero or one of B, D or E is NR^1 or O;

G is CR^mR^n;

K is NR^1;

R^1 is (1-6C)alkyl [optionally substituted with one to five fluoros], (1-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], (1-6C)alkylC(=O)- or (1-6C alkoxy)C=O-;

R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently H, OH, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], (2-6C)cyanoalkyl, (1-6C)alkoxy [optionally substituted with one to five fluoros], or (1-3C alkoxy)(2-6C)alkoxy [optionally substituted with one to five fluoros],

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k, together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring,

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group,

and wherein only one of R^d and R^e can be OH and neither is OH if B is connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom;


R^m is H, (1-3C)alkyl [optionally substituted with 1-5 fluoros], cyclopropyl or cyclobutyl, and

R^n is H or (1-3C)alkyl [optionally substituted with 1-5 fluoros], or

R^m and R^n together form an oxo group;

R^p is H, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], or (2-6C)cyanoalkyl;

Ring C is formula **C-1**



C-1 ;

R^3 is (1-6C)alkyl, hydroxy(1-6C)alkyl, Ar^2, $hetCyc^1$, (3-7C)cycloalkyl, or $hetAr^2$;

Ar^2 is phenyl optionally substituted with one or more groups independently selected from halogen and (1-6C)alkyl;

$hetCyc^1$ is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

$hetAr^2$ is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen;

R^4 is OH, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, amino(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-3C)alkylsulfonamido(1-6C)alkyl, sulfamido(1-6C)alkyl, hydroxycarbonyl(1-6C)alkyl, $hetAr^3$(1-6C)alkyl, Ar^3(1-6C)alkyl, (1-6C)alkoxy, monofluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, hydroxyl-carbonyl(1-6C)alkoxy, $hetCyc^2$(1-6C)alkoxy, $hetAr^3$(1-6C)alkoxy, Ar^3(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (1-3C alkylsulfonyl)(1-6C)alkoxy, (3-6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(1-6C)alkyl], $hetAr^4$, $hetAr^4$-O-, Ar^4, $hetCyc^2(O)CH_2$-, (1-4C alkoxycarbonyl)(1-6C)alkoxy, hydroxycarbonyl(1-6C)alkoxy, aminocarbonyl(1-6C)alkoxy, $hetCyc^2C(=O)$(1-6C)alkoxy, hydroxy(1-3C alkoxy)(1-6C)alkoxy, hydroxytrifluoro(1-6C)alkoxy, (1-3C)alkylsulfonamido(1-6C)alkoxy, (1-3C)alkylamido(1-6C)alkoxy, di(1-3C alkyl)amino-carboxy, $hetCyc^2C(=O)O$-, hydroxydifluoro(1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, (1-6C)alkoxycarbonyl, hydroxylcarbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, $hetCyc^3$, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)oxadiazolonyl, $hetAr^5$ or $hetCyc^4$-O-;

hetCyc^2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, and (1-6C)acyl;


hetCyc^3 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, (1-6C)alkyl, trifluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, (1-6C)acyl-, (1-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl;

hetAr^3 is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (1-6C)alkyl;

Ar^3 is phenyl optionally substituted with (1-4C)alkoxy;

hetAr^4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl, trifluoro(1-6C)alkyl, difluoro(1-6C)alkyl, fluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH_2- (3-6C cycloalkyl)C(=O)-, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylsulfonyl, NH_2, (1-6C alkyl)amino, di(1-6C alkyl)amino, (1-3C trifluoroalkoxy), fluoro(1-6C alkyl)amino, difluoro(1-6C alkyl)amino, trifluoro(1-6C alkyl)amino, and (3-4C cycloalkyl)amino;

hetAr^5 is a group selected from the structures:



where R^z is (3-4C)cycloalkyl or (1-3C)alkyl (optionally substituted with 1-3 fluoros), wherein each of said hetAr^5 groups is optionally further substituted with one or more groups independently selected from F and (1-3C)alkyl optionally substituted with 1-3 fluoros;

hetCyc^4 is a 7-8 membered bridged heterocycle having a ring nitrogen atom and optionally substituted with one or more groups independently selected from (1-6C)alkyl and halogen;

Ar^4 is phenyl optionally substituted with one or more groups independently selected from (1-6C)alkyl, halogen, CN, CF_3, CF_3O-, (1-6C)alkoxy, (1-6Calkyl)OC(=O)-, aminocarbonyl, (1-6C)alkylthio, hydroxy(1-6C)alkyl, (1-6C alkyl)SO_2-, HOC(=O)- and (1-3C alkoxy)(1-3C alkyl)OC(=O)-; and

R^5 is (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl, (1-4C alkyl)OC(=O)-, (1-6C)alkylthio, (3-4C)cycloalkyl, amino, aminocarbonyl, trifluoro(1-3C alkyl)amido, or phenyl (optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy); or

R^4 and R^5 together with the atoms to which they are attached form 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or two substituents independently selected from (1-6C alkyl)C(=O)O-, (1-6C)acyl, (1-6C)alkyl and oxo, and said sulfur ring atom is optionally oxidized to S(=O) or SO_2.

2. A compound according to claim 1, wherein X is O.

3. A compound according to any one of claims 1-2, wherein zero to four of R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently H, OH, (1-6C)alkyl [optionally substituted with one to five fluoros], (3-6C)cycloalkyl [optionally substituted with one to five fluoros], (1-3C alkoxy)(2-6C)alkyl [optionally substituted with one to five fluoros], hydroxy(2-6C)alkyl [optionally substituted with one to five fluoros], (2-6C)cyanoalkyl, (1-6C)alkoxy [optionally substituted with one to five fluoros], or (1-3C alkoxy)(2-6C)alkoxy [optionally substituted with one to five fluoros],

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k, together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring, or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group, and the remainder are hydrogen, wherein only one of R^d and R^e can be OH and neither is OH if B is connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom.

4. A compound according to claim 3, wherein zero to two of R^d, R^e, R^f, R^g, R^h, R^i, R^j and R^k are independently OH, methyl, methoxy, $CH_3OCH_2CH_2O$-, or cyclopropyl,

or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k, together with the carbon atom to which they are attached form a (3-6C)cycloalkyl, oxetanyl or azetidinyl ring, or one of a pair of R^d and R^e, or R^f and R^g, or R^h and R^i, or R^j and R^k form an oxo group, and the remainder are hydrogen, wherein only one of R^d and R^e can be OH and neither is OH if B is connected to a heteroatom, and only one of R^f and R^g can be OH and neither is OH if D is connected to a heteroatom, and only one of R^h and R^i can be OH and neither is OH if E is connected to a heteroatom, and only one of R^j and R^k can be OH and neither is OH if F is connected to a heteroatom.

5. A compound according to any one of claims 1-4, wherein Ring A is A-1.

6. A compound according to claim 5, wherein B is a bond or CR^dR^e, D is a bond or CR^fR^g, E is a bond or CR^hR^i, and F is CR^jR^k, provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms.

7. A compound according to any of claims 1-6, wherein Y is H, halogen or (1-3C alkoxy)(1-6C)alkyl.

8. A compound according to any of claims 1-7, wherein R^a, R^b and R^c are independently selected from halogen, (1-3C)alkyl, (1-3C)alkoxy and CN.

9. A compound according to any one of claims 1-8, wherein:

R^4 is OH, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(1-6C)alkyl, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, amino(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, (1-3C)alkylsulfonamido(1-6C)alkyl, sulfamido(1-6C)alkyl, hydroxycarbonyl(1-6C)alkyl, $hetAr^3$(1-6C)alkyl, Ar^3(1-6C)alkyl, (1-6C)alkoxy, monofluoro(1-6C)alkoxy, difluoro(1-6C)alkoxy, trifluoro(1-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, hydroxyl-carbonyl(1-6C)alkoxy, $hetCyc^2$(1-6C)alkoxy, $hetAr^3$(1-6C)alkoxy, Ar^3(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (1-3C alkylsulfonyl)(1-6C)alkoxy, (3-6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(1-6C)alkyl], $hetAr^4$, $hetAr^4$-O-, Ar^4, $hetCyc^2(O)CH_2$-, (1-4C alkoxycarbonyl)(1-6C)alkoxy, hydroxycarbonyl(1-6C)alkoxy, aminocarbonyl(1-6C)alkoxy, $hetCyc^2C(=O)$(1-6C)alkoxy, hydroxy(1-3C alkoxy)(1-

6C)alkoxy, hydroxytrifluoro(1-6C)alkoxy, (1-3C)alkylsulfonamido(1-6C)alkoxy, (1-3C)alkylamido(1-6C)alkoxy, di(1-3C alkyl)amino-carboxy, $hetCyc^2C(=O)O$-, hydroxydifluoro(1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, (1-6C)alkoxycarbonyl, hydroxylcarbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, $hetCyc^3$, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)oxadiazolonyl, or $hetAr^5$;

and

R^5 is (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl, (1-4C alkyl)OC(=O)-, (1-6C)alkylthio, (3-4C)cycloalkyl, amino, aminocarbonyl, trifluoro(1-3C alkyl)amido, or phenyl (optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy).

10. A compound according to claim 9, wherein R^4 is selected from (1-6C)alkoxy, $hetAr^4$ and $hetAr^5$.

11. A compound according to claim 10, wherein R^4 is $hetAr^4$ or $hetAr^5$.

12. A compound according to any one of claims 1-11, wherein R^5 is selected from halogen, CN, (1-6C)alkyl, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy.

13. A compound according to claim 12, wherein R^5 is (1-6C)alkyl.

14. A compound according to any one of claims 1-13, wherein R^3 is selected from Ar^2 and (1-6C)alkyl.

15. A compound according to claim 14, wherein R^3 is Ar^2.

16. A compound according to claim 9, where R^4 is selected from H, (1-6C)alkyl, trifluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, cyano(1-6C)alkyl, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy, monofluoro(1-6C)alkoxy, cyano(1-6C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, $hetCyc^2$(1-6C)alkoxy, Ar^3(1-6C)alkoxy, (1-4C alkoxy)(1-6C)alkoxy, (1-3C alkylsulfonyl)(1-6C)alkoxy, (3-6C)cycloalkyl, $hetAr^4$, $hetAr^4$-O-, Ar^4, and $hetAr^5$.






17. A compound according to claim 16, wherein R^4 is $hetCyc^2$(1-6C)alkoxy.






18. A compound according to claim 17, wherein R^5 is (1-6C)alkyl.






19. A compound according to claim 18, wherein R^3 is Ar^2.





20. A compound according to claim 19, wherein Y is H.




21. A compound according to claim 1, selected from





Ex. #	Structure
1	
2	
4	
5	
6	




Ex. #	Structure
7	
8	
9	
10	
11	





Ex. #	Structure
12	
13	
14	
15	
16	





Ex. #	Structure
17	
18	
19	
20	




Ex. #	Structure
21	
25	
26	





Ex. #	Structure
27	
29	
30	
31	





Ex. #	Structure
32	
33	
34	




Ex. #	Structure
35A	
35B	
36	
37	





Ex. #	Structure
38	
39	
40	
41	




Ex. #	Structure
42	
43	
44	





Ex. #	Structure
45	
46	
49	
51	





Ex. #	Structure
52	
53	
54	
55	




Ex. #	Structure
56	
57	
58	





Ex. #	Structure
59	
60	
61	
62	





Ex. #	Structure
63	
64	
65	





Ex. #	Structure
66	
67	
68	
69	





Ex. #	Structure
70	
71	
72	
73	





Ex. #	Structure
74	
75	
76	






Ex. #	Structure
77	
78	
79	
80	






Ex. #	Structure
81	
82	
83	
84	






Ex. #	Structure
85	
86	
87	
88	






Ex. #	Structure
89	
90	
91	
92	






Ex. #	Structure
93	
94	
95	
96	







Ex. #	Structure
97	
98	
99	
100	
101	






Ex. #	Structure
102	
103	
104	
105	
106	




Ex. #	Structure
107	
108	
109	
110	
111	




Ex. #	Structure
112	
113	
114	
115	
116	





Ex. #	Structure
117	
118	
119	
120	
121	





Ex. #	Structure
122	
123	
124	
125	
126	
127	





Ex. #	Structure
128	
129	
130	
131	
132	





Ex. #	Structure
133	
134	
135	





Ex. #	Structure
136	
137	
138	


Ex. #	Structure
139	
140	
141	
142	

Ex. #	Structure
143	
144	
146	
147	

Ex. #	Structure
148	
149	
150	
151	



Ex. #	Structure
152	
153	
154	
155	




Ex. #	Structure
156	
157	
158	
159	





Ex. #	Structure
160	




or a pharmaceutically acceptable salt thereof.





22. A compound of claim 21, selected from





Ex. #	Structure
37	
55	




Ex. #	Structure
56	
57	
58	






Ex. #	Structure
59	
60	
61	
62	





Ex. #	Structure
63	
64	
65	





Ex. #	Structure
66	
67	
68	
69	




Ex. #	Structure
70	
71	
72	
73	

Ex. #	Structure
74	
75	
76	

Ex. #	Structure
77	
78	
101	
118	
121	





Ex. #	Structure
123	
127	
128	
137	





Ex. #	Structure
138	
139	
140	
141	





Ex. #	Structure
142	
154	
155	




23. A compound of claim 21, selected from:

Ex. #	Structure

Ex. #	Structure
74	
80	
82	
84	

Ex. #	Structure
86	
87	
117	
122	

Ex. #	Structure
129	
144	
146	
147	

Ex. #	Structure
151	
153	
155	

24. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

25. A compound of Formula **I** as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24, for use in therapy.

26. A compound of Formula **I** as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24, for use in the treatment of pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

27. The compound or pharmaceutical composition of claim 26, for use in the treatment of pain.

28. The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is chronic pain.

29. The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is acute pain.


30. The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is inflammatory pain, neuropathic pain, pain associated with cancer, pain associated with surgery or pain associated with bone fracture.

31. The compound or pharmaceutical composition for use as defined in claim 26, wherein said cancer is a cancer having a dysregulation of TrkA.

32. A compound of Formula **I** as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for treating pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.


33. A process for the preparation of a compound of claim 1, which comprises:

(a) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **III**



III


in the presence carbonyldiimidazole or triphosgene and a base; or

(b) for a compound of Formula **I** where X is S, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **III**



III


in the presence di(1H-imidazol-2-yl)methanethione and a base; or

(c) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **IV**



IV


where L^1 is a leaving group, in the presence of a base; or

(d) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **V**



V


where L^2 is a leaving group, with a corresponding compound having the formula **III**



III


in the presence of a base; or

(e) for a compound of Formula **I** where X is O, activating a corresponding compound having the formula **VI**



VI


with diphenylphosphoryl azide followed by coupling the activated intermediate with a corresponding compound having the formula **III**



III


in the presence a base; or

(f) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **II**



II


with a corresponding compound having the formula **VII**



VII


in the presence of a base; or

(g) for a compound of Formula **I** where X is O, coupling a corresponding compound having the formula **VIII**



VIII

with a corresponding compound having the formula **III**



III

in the presence of a base; and

optionally removing protecting groups and optionally preparing a pharmaceutically acceptable salt thereof.